• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Daiichi Sankyo Ltd ADR (OP: DSNKY )

    29.59 +0.25 (+0.87%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 249,627
    Open 29.64
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 29.34
    Today's Range 29.54 - 29.75
    52wk Range 26.05 - 42.48
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
    AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... 
    Via Benzinga
    Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
    Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
    Via Benzinga

    Performance

    YTD
    +9.23%
    +9.23%
    1 Month
    -9.95%
    -9.95%
    3 Month
    -26.30%
    -26.30%
    6 Month
    -16.41%
    -16.41%
    1 Year
    +11.12%
    +11.12%

    More News

    Read More
    AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
    Via Benzinga
    Is Merck Stock Undervalued After Its Colossal Earnings Growth?
    Via MarketBeat
    DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024
    Via InvestorPlace
    Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
    Via Benzinga
    Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
    Via Benzinga
    Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
    Via Benzinga
    Exposures Product Safety
    The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
    Via InvestorPlace
    FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
    Via Benzinga
    Exposures Product Safety
    Why Is AstraZeneca Stock Trading Lower On Tuesday?
    Via Benzinga
    DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
    Via InvestorPlace
    Double Good News For AstraZeneca's Breast Cancer Drugs
    Via Benzinga
    AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
    Via Benzinga
    Exposures Product Safety
    What's Going On With Pfizer Stock Today?
    Via Benzinga
    Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
    Via Benzinga
    Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
    Via Benzinga
    Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
    Via The Motley Fool
    Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
    Via Benzinga
    AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
    Via Benzinga
    FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
    Via Benzinga
    Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
    Via Benzinga
    AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
    Via Benzinga
    Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
    Via Benzinga
    AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.